049960 — Cell Biotech Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMicro CapSuper Stock

Annual income statement for Cell Biotech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	45,582	46,873	50,526	53,787	49,913
Cost of Revenue
Gross Profit	34,725	35,683	37,951	38,975	36,060
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	41,915	39,617	44,458	51,674	43,117
Operating Profit	3,668	7,257	6,068	2,113	6,796
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,402	12,320	10,172	6,880	15,610
Provision for Income Taxes
Net Income After Taxes	3,189	10,613	8,281	6,304	15,127
Net Income Before Extraordinary Items
Net Income	3,189	10,613	8,281	6,304	15,127
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,189	10,613	8,281	6,304	15,127
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	449	1,497	1,199	932	2,209
Dividends per Share